SeaBeLife, a Brittany, France-based biotech company, raised €1.37M in financing from Bpifrance Funds.
The financing will be paid out in two installments via the French government’s ‘Future Investments Program’:
- €959k ($1.04M) in the form of a repayable advance and
- €411k ($447k) in the form of subsidies.
This financing, which has been granted in connection with the French government’s ‘Deeptech Plan’, will contribute to research into first-in-class drug candidates for the treatment of acute liver, kidney, heart and brain disease.
The company intends to use the funds to develop drug candidates with the ability to simultaneously inhibit necroptosis and ferroptosis, two modes of regulated cell death that are activated in individuals living with certain pathologies.
Founded in March 2019 and led by CEO and co-founder Morgane Rousselot, who holds a PhD in biochemistry, SeaBeLife is a biotechnology company specialized in the development of drug candidates that block cellular necrosis in order to protect or regenerate organs affected by severe pathologies – for which there are no alternative, effective treatments.
The company primarily targets acute pathologies of the liver and kidneys, whilst leading other research activities in ocular and degenerative conditions.
The company is based on the research works of Stéphane Bach, PhD, CNRS research engineer, Marie-Thérèse Dimanche-Boitrel, research director at IRSET (the French institute for research in environmental and occupational health) and Claire Delehouzé, a biotechnology engineer, co-founder and CTO at SeaBeLife.
SeaBeLife currently employs six people.
FinSMEs
15/03/2022